Press Releases Mereo BioPharma Group plc

Equities

MREO

US5894921072

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.74 ^USD	-2.49%		+3.79%	+18.61%

Apr. 26	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	MT
Apr. 24	European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mereo BioPharma : UK Annual Report 2023	Apr. 25	PU
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference	Mar. 05	AQ
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments	Jan. 08	AQ
Mereo BioPharma : Submission of Matters to a Vote of Security Holders - Form 6-K	Dec. 18	PU
Mereo BioPharma : INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K - Form 6-K	Nov. 29	PU
Mereo BioPharma : THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION - Form 6-K	Nov. 16	PU
"Discoveries Unlocked: Nasdaq Small-Cap Biotech Medical Stocks Emerge" VTAK, MNTS, MREO, PCSA, MTNB	23-10-18	AQ
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta	23-10-16	AQ
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)	23-10-14	AQ
Mereo BioPharma : Change in Registrant's Certifying Accountant - Form 6-K	23-09-20	PU
Mereo BioPharma : Condensed Consolidated Statements of Comprehensive Loss - Form 6-K	23-09-07	PU
Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update	23-09-07	AQ
Mereo BioPharma to Present at the Jefferies Healthcare Conference	23-05-31	AQ
Mereo BioPharma : Harnessing Agility and Customer Intimacy to Drive Success in the Rare Disease Space	23-05-25	PU
Phase 2 Data from 'ASTRAEUS' Trial of Mereo BioPharma's Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference	23-05-24	AQ
Mereo BioPharma : Submission of Matters to a Vote of Security Holders - Form 6-K	23-05-23	PU
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market	23-05-08	AQ
Mereo BioPharma to Participate in Fireside Chat at the 22nd Annual Needham Healthcare Conference	23-04-13	AQ
Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease	23-03-21	GL
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference	22-11-08	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Mereo BioPharma Group plc

Equities

MREO

US5894921072

Press Releases

Filters